Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Quadrivalent Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The quadrivalent market has demonstrated significant expansion in recent years. It is projected to climb from $9.51 billion in 2025 to $10.44 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. The observed growth during previous periods can be linked to the rising occurrence of influenza, governmental vaccination drives, progress in vaccine development, increased public understanding concerning flu prevention, and the initial uptake of quadrivalent vaccines in advanced regions.
The quadrivalent market is projected to experience swift expansion in the coming years, with its size anticipated to reach $15.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This growth during the projection period is attributed to several factors, including an increased need for comprehensive influenza protection, advancements in vaccine delivery methods, the expansion of immunization initiatives in developing regions, greater financial commitments to biotechnology and personalized medicine, and supportive reimbursement frameworks and governmental aid. Key developments expected in the forecast timeframe encompass improvements in vaccine composition, broadened immunization schedules for various age groups, breakthroughs in cold chain and distribution networks, multi-strain influenza coverage, and adherence to regulatory standards and quality assurance.
Get A Free Sample Report With In-Depth Market Insights:
Quadrivalent Market Growth Factors Behind Sustained Expansion
Global increases in immunization coverage are projected to boost the quadrivalent market. This coverage indicates the percentage of a population that has received particular or recommended vaccines within a given period. As immunization coverage expands, the demand for vaccines rises, particularly for quadrivalent vaccines, which protect against four strains and are often included in standard vaccination schedules to tackle multiple diseases with a single administration. For example, the World Health Organization, an international public health body based in Switzerland, reported in July 2025 that worldwide coverage for the initial dose of the HPV vaccine among girls climbed from 27% in 2023 to 31% in 2024. Consequently, increasing global immunization coverage is anticipated to fuel the future growth of the quadrivalent market.
Quadrivalent Market Segment Landscape And Growth Outlook
The quadrivalent market covered in this report is segmented –
1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray
2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies
3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases
4) By Age Group: Pediatric, Adult
5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)
Subsegments:
1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery
2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection
3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray
Quadrivalent Market Industry Trends Fueling Future Revenue Growth
Leading companies in the quadrivalent market are concentrating on developing safer, innovative vaccine delivery technologies, such as nano-particle technology, to boost their market revenues. This nano-particle technology mimics the external structure of viruses using virus-like particles (VLPs) without including live genetic material, thereby improving both safety and the immune response. For instance, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, launched its advanced Quadrivalent Influenza Vaccine. This sophisticated immunization is engineered to offer protection against four distinct strains of the influenza virus: two A strains (H1N1 and H3N2) and two B strains. This specific quadrivalent formulation enhances the vaccine’s efficacy by targeting a broader spectrum of circulating influenza viruses, making it particularly effective during flu seasons. The aQIV aims to stimulate a robust immune response, consequently reducing the incidence of influenza-related morbidity and mortality. Its development underscores continuous efforts to improve public health outcomes in the context of evolving viral strains.
Quadrivalent Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the quadrivalent market are AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)
View The Full Quadrivalent Market Report:
Quadrivalent Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the quadrivalent market in 2025. The regions covered in the quadrivalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
